Aug 27 (Reuters) - The EU on Friday approved U.S.-based Biomarin Pharmaceutical Inc's treatment for one of the most common forms of dwarfism, the first such approval in the region for a therapy to treat the underlying cause of achondroplasia, the company said. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
92.06 USD | +2.87% | +1.31% | -4.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.52% | 17.47B | |
-2.86% | 87.37B | |
+4.08% | 41.01B | |
-25.35% | 28.08B | |
+54.25% | 24.72B | |
-42.09% | 11.69B | |
-17.77% | 11.6B | |
-12.10% | 11.56B | |
+1.27% | 8.44B | |
+3.32% | 7.72B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- BioMarin Pharmaceutical : Europe clears Biomarin drug for type of dwarfism in region's first